Second-generation antidepressant: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

2 February 2023

1 May 2012

29 March 2012

27 December 2011

21 October 2011

13 February 2011

10 February 2010

18 January 2010

  • curprev 20:0520:05, 18 January 2010imported>David Ellis 8,340 bytes 0 correct link
  • curprev 19:4619:46, 18 January 2010imported>David Ellis 8,340 bytes 0 correct link
  • curprev 17:2917:29, 18 January 2010imported>David Ellis 8,340 bytes +162 rewrite and expand, avoiding the use of a direct quotation as a substantial portion of the introduction
  • curprev 17:0517:05, 18 January 2010imported>David Ellis 8,178 bytes +16 consistency, since we're subsequently describing MAO-A and MAO-B as a single enzyme
  • curprev 16:5516:55, 18 January 2010imported>David Ellis 8,162 bytes +2,909 reorganize, expand
  • curprev 14:4614:46, 18 January 2010imported>David Ellis 7,953 bytes −57 remove blank table
  • curprev 14:2214:22, 18 January 2010imported>David Ellis 8,047 bytes +22 Increased levels of dopamine are also vitally important to the clinical efficacy of monoamine oxidase inhibitors (and are usually lacking in newer generations of antidepressants)
  • curprev 14:0414:04, 18 January 2010imported>David Ellis 8,025 bytes 0 spelling
  • curprev 14:0114:01, 18 January 2010imported>David Ellis 8,025 bytes +15 It's a 5-HT2A antagonist, actually -- see http://www.ncbi.nlm.nih.gov/pubmed/9098663?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract

8 January 2010

12 October 2009

15 June 2009

29 January 2009

19 December 2008

18 November 2008

15 May 2008

25 February 2008